Abstract Previous studies indicated that the increase in protein kinase C (PKC)-mediated myofilament protein phosphorylation observed in failing myocardium might be detrimental for contractile function. This study was designed to reveal and compare the effects of PKCa-and PKCemediated phosphorylation on myofilament function in human myocardium. Isometric force was measured at different [Ca 2? ] in single permeabilized cardiomyocytes from failing human left ventricular tissue. Activated PKCa and PKCe equally reduced Ca 2? sensitivity in failing cardiomyocytes (DpCa 50 = 0.08 ± 0.01). Both PKC isoforms increased phosphorylation of troponin I-(cTnI) and myosin binding protein C (cMyBP-C) in failing cardiomyocytes. Subsequent incubation of failing cardiomyocytes with the catalytic subunit of protein kinase A (PKA) resulted in a further reduction in Ca 2? sensitivity, indicating that the effects of both PKC isoforms were not caused by crossphosphorylation of PKA sites. Both isozymes showed no effects on maximal force and only PKCa resulted in a modest significant reduction in passive force. Effects of PKCa were only minor in donor cardiomyocytes, presumably because of already saturated cTnI and cMyBP-C phosphorylation levels. Donor tissue could therefore be used as a tool to reveal the functional effects of troponin T (cTnT) phosphorylation by PKCa. Massive dephosphorylation of cTnT with alkaline phosphatase increased Ca 2? sensitivity. Subsequently, PKCa treatment of donor cardiomyocytes reduced Ca 2? sensitivity (DpCa 50 = 0.08 ± 0.02) and solely increased phosphorylation of cTnT, but did not affect maximal and passive force. PKCa-and PKCe-mediated phosphorylation of cMyBP-C and cTnI as well as cTnT decrease myofilament Ca 2? sensitivity and may thereby reduce contractility and enhance relaxation of human myocardium.
Introduction
The protein kinase C (PKC) family consists of a number of different isozymes with different substrate specificities [16] . In the failing human heart PKC activity and the expression of the Ca 2? dependent isoform PKCa are increased [6] . PKCa has been shown to play an important role in the development of cardiac hypertrophy and heart failure [7, 12, 13] . PKCa directly phosphorylates regulatory myofilament proteins such as cardiac troponin I (cTnI) and cardiac troponin T (cTnT) [17] . PKCa also phosphorylates protein phosphatase inhibitor 1, which alters the activity of protein phosphatase 1 [7, 31] . PKCe is another (Ca 2? independent)myofilaments (and the sarcolemma) [10, 15, 16] . Several myofilament regulatory proteins [myosin binding protein C (cMyBP-C), cTnT, cTnI] serve as targets for PKCe [24, 40] . Moreover, transgenic mice overexpressing constitutively active PKCe slowly develop dilated cardiomyopathy with failure [11] . Studies in rodent myocardium indicated that cTnT and cTnI phosphorylation influence Ca 2? sensitivity and were involved in the PKC-mediated depression of the maximal force generating capacity [8, 18, 32, 33] . Using an in vitro motility assay, an association was observed between the increased PKC expression in failing human hearts and a reduction of the force exerted on thin filaments [29] . Moreover, a recent study using two different animal models of congestive heart failure, in which PKCa expression and activation was considerably increased, provided evidence that augmented PKCa-induced myofilament protein phosphorylation contributes to myofilament dysfunction by a reduction of maximum force and of Ca 2? sensitivity [2] . The expression of the different PKC isoforms, with different substrate specificity, varies between rodents and humans and with different disease states [1, 19] . This may affect the basal phosphorylation status of the myocardium and thus influence the effects of the kinases on Ca 2? sensitivity and force development per se. Specific information on the impact of the different PKC isoforms on contractile function in human myocardium is lacking. Therefore, we investigated the impact of PKCa and PKCe in human tissue from donor and end-stage failing hearts obtained during transplant surgery.
Materials and methods

Human ventricular tissue
Left ventricular (LV) transmural tissue samples were obtained during heart transplantation surgery from ten patients with end-stage dilated cardiomyopathy (NYHA IV) and four non-failing donor hearts ( Table 1) 
Force measurements
Cardiomyocytes were mechanically isolated, Triton X-100 permeabilized and mounted in the experimental set-up at a sarcomere length of 2.2 lm. Force measurements and maximal rate of force redevelopment measurements were performed as described previously [28, [35] [36] [37] .
Briefly, a single cardiomyocyte was mounted between a force transducer and piezoelectric motor. After transferring the cardiomyocyte from relaxing solution (5.89 mM Na 2 ATP, 6.48 mM MgCl 2 , 40.76 mM propionic acid (Kprop), 100 mM Bis-2-aminoethanesulfonic acid (BES), 7.0 mM ethylene glycol tetra acetic acid (EGTA), 14.5 mM phosphocreatine disodium salt (CrP), pH 7.10 at 15°C, pCa 9) to activating solution (5.97 mM Na 2 ATP, 6.28 mM MgCl 2 , 40.64 mM Kprop, 100 mM BES, 7.0 mM CaEGTA, 14.5 mM CrP, pH 7.10 at 15°C, pCa 4.5), isometric force was measured. After reaching steady force, the cardiomyocyte was 20% reduced in length within 2 ms and restretched after 30 ms (slack test). During this slack test, force first dropped to zero and after the restretch quickly redeveloped to the original steady state level. A single exponential was fitted to estimate the rate constant of force redevelopment at maximal activation (K tr -max). Calcium sensitivity (pCa 50 [38] .
After the initial force-pCa series, the myocyte was incubated for 60 min at 20°C in a Ca 2? -containing solution (pCa 5.9) containing 6 mM dithiothreitol (DTT), 1 lM PMA (phorbol 12-myristate 13-acetate; Sigma), 50 nM calyculin A (calA, Sigma) without kinase (time control), with 10 lg/mL human recombinant PKCa (Sigma P1782; batch 93K0330) or 10 lg/mL human recombinant PKCe (Sigma P1164; batch 060K1890). CalA was added to the incubation buffer to prevent protein dephosphorylation during incubation. The concentrations of the active PKC isoforms were saturating as no further effect on cardiomyocyte function were seen when the concentration was doubled. A separate group of failing myocytes was incubated for 40 min at 20°C in relaxing solution (see above) containing 6 mM DTT and 100 U/mL of the catalytic subunit of protein kinase A (PKA, Sigma P2645; batch 35H9522). After the incubation the force-pCa series was repeated. A third force-pCa series was performed to study sequential effects, i.e., PKC isoforms after PKA or visa versa. The effect of PKCa was also investigated upon pretreatment of failing and donor cardiomyocytes with alkaline phosphatase (AP, calf intestinal, New England Biolabs; 2,000 U/mL) in relaxing solution (pCa 9) containing 6 mM DTT and 50 lL/mL protease inhibitor cocktail (PIC, Sigma, P8340) for 60 min at 20°C. All force measurements were performed at 15°C.
Protein analysis
Endogenous protein phosphorylation
To preserve the endogenous phosphorylation status, frozen tissue samples (*1 mg dry weight) were homogenized in liquid nitrogen and resuspended in 1 mL cold (-20°C) 10% trichloroacetic acid solution (TCA; dissolved in acetone containing 0.1% (w/v) DTT) [27] . Tissue homogenates were kept for 1 h at -80°C and slowly heated to room temperature by stepwise increments in temperature as follows: 20 min at -20°C, 20 min at 4°C and 20 min at room temperature (20 ± 2°C). The homogenates were thoroughly mixed on a vortex between all steps. Thereafter, the tissue homogenates were centrifuged at 12,000g for 15 min and tissue pellets were washed with 1 mL of 0.2% (w/v) DTT-acetone solution and shaken for 5 min at room temperature. Centrifugation, washing and shaking was repeated three times. Thereafter tissue pellets were freezedried and homogenized in 1D-sample buffer containing 15% glycerol, 62.5 mM Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT (final concentration 2.5 lg dry weight/lL). To determine basal phosphorylation status of myofilament proteins, myocardial samples (TCA treated 20 lg/lane) were separated on gradient gels (Criterion Tris-HCl 4-15% gel, BioRad) and stained with Pro-Q diamond phosphoprotein gel stain (Pro-Q; Molecular Probes) in conjunction with SYPRO Ruby staining (Molecular Probes) of the gels [43] . The phosphorylation signals for myofilament proteins were normalized to the intensities of the SYPRO Rubystained myosin binding protein C (cMyBP-C) bands. All signals were quantified using the luminescent image analyzer LAS-3000 (Fuji Science Imaging Systems) and Aida image analyzer software (Isotopenmebgeräte GmbH, Staubenhardt, Germany).
Alterations in myofilament protein phosphorylation
To investigate the effect of the PKC isoforms as well as of PKA and AP on myofilament protein phosphorylation 600 lg (dry weight) of tissue was treated in with Triton X-100 (0.5%) in relaxing solution (pCa 9) containing PIC (5 lL/mL), phosphatase inhibitor cocktail (PhIC2, Sigma, P5726, 5 lL/mL) and calA (50 nM) for 5 min at room temperature, washed twice with relaxing solution without Triton X-100 and subsequently incubated for 60 min (or 40 min for PKA) at 20°C in 100 lL of (1) relaxing solution containing PIC (50 lL/mL), PhIC2 (50 lL/mL), calA (50 nM) and DTT (6 mM)(=control incubation); (2) activating solution (pCa 5.9) containing PIC (50 lL/mL), PhIC2 (50 lL/mL), calA (50 nM), DTT (6 mM), PMA (1 lM) and PKCa (10 lg/mL) or (3) PKCe (10 lg/mL); (4) relaxing solution containing PIC (50 lL/mL), PhIC2 (50 lL/mL), calA (50 nM), DTT (6 mML) and PKA (100 U/mL); (5) relaxing solution containing PIC (50 lL/mL), DTT (6 mM) and AP (2,000 U/mL). Part of the tissue treated with AP was washed and subsequently incubated with PKCa (see incubation no. 2). Subsequently, tissue was treated with TCA and analyzed using ProQ-stained gradient gels as described above.
To investigate the effect of PKCa phosphorylation of titin, tissue samples with a final concentration of *10 lg/lL dry weight were homogenized in 100-150 lL sample buffer consisting of 0.55 M Tris HCL, 0.55 M EDTA, 10% glycerol, 1% b-mercaptoethanol, 20% (w/v) SDS, 8 lL/mL leupeptin (Peptin-institute, Japan), 10 lL/mL PhIC1 (Sigma, P2850) and PhIC2, pH6.8. Myocardial samples (*100 lg/lane) were separated on agarose strengthened 2% sodium dodecyl sulfate-polyacrylamide gels and stained with Pro-Q diamond phosphoprotein gel stain in conjunction with Sypro Ruby staining [5] . Staining and analysis as described above.
Data analysis
Force-pCa relations were fit to the Hill equation as described previously [37] . Values are given as mean ± SEM of n experiments. Cardiomyocyte force values for donor and failing samples were compared using an unpaired Student t test. Effects of incubations without or with PKCa, PKCe, PKA or AP were tested with paired Student t test. Repeated measures ANOVA followed by a Bonferroni post hoc test was used when studying the Basic Res Cardiol (2010) 105:289-300 291 effects of sequential incubations with the PKC isoforms, PKA or AP. P \ 0.05 was considered significant.
Results
PKCa and PKCe phosphorylation of cTnI and cMyBP-C decrease Ca 2? sensitivity in failing myocardium Direct incubation of the cardiomyocytes from failing hearts with saturating amounts of PKCa (n = 14 cardiomyocytes) and PKCe (n = 7 cardiomyocytes) resulted in a decrease in Ca 2? sensitivity (pCa 50 ) (Fig. 1a, b ). Both PKC isoforms had no effect on maximal force (F max ). Passive force (F pas ) was reduced after PKCa treatment, whereas PKCe had no significant effect on F pas (Table 2a) . F max , F pas and pCa 50 did not change in the absence of kinases (time control; n = 6 failing cardiomyocytes), while the steepness of the force-pCa relationship (nH) slightly decreased (Table 2a) . Figure 1c shows a phosphoprotein (ProQ) stained 1D gel of failing tissue samples treated with PKCa and PKCe, at concentrations of 10 and 50 lg/mL. The phosphorylated active forms of PKCa and PKCe became apparent in the incubations with 50 lg/mL kinase. Gels were subsequently stained with SYPRO Ruby to correct for differences in protein loading. The phosphorylation levels with 50 lg/mL kinase were similar to the incubations with 10 lg/mL kinase, indicating that the standard concentrations of 10 lg/mL kinase yielded the maximum obtainable phosphorylation level. To further investigate if PKCa and PKCe are able to phosphorylate cTn, recombinant human troponin complex [43] was incubated with both isoforms. The results on the recombinant, non-phosphorylated troponin complex clearly indicate that PKCa and PKCe both phosphorylate cTnT and cTnI and that the efficacy of PKCe was less than that of PKCa (Fig. 1d) . Figure 1e shows that PKCa (n = 5) and PKCe (n = 2) caused pronounced (2-to 3-fold) increases in cTnI and cMyBP-C phosphorylation in failing myocardium (relative to the control incubation without kinase which was set to 1). The relative increase in cMyBP-C phosphorylation by PKCe (3.4 ± 0.5) was somewhat higher to that observed with PKCa (2.1 ± 0.4), while phosphorylation of cTnI with PKCe (1.6 ± 0.1) was lower compared with PKCa (2.9 ± 0.6). A minor increase in desmin phosphorylation was observed with both isoforms, while only PKCa slightly increased cTnT phosphorylation. No effects were observed on phosphorylation of myosin light chain 2 (MLC-2). As PKCa lowered passive force, the effect of PKCa incubation on the phosphorylation of cardiac titin was analyzed in failing (n = 5) and donor (n = 6) tissue. Incubation with PKCa did not result in a significant change in titin phosphorylation in both donor and failing tissue (Fig. 2a, b) .
To address the origin of the shift in Ca 2? sensitivity in failing hearts, cells were treated with PKA after incubation with PKCa and e. This resulted in a further reduction in Ca 2? sensitivity (Fig. 3a, b) , without any significant effect on F max and F pas (Table 2a) . Reversal of the PKA and PKCa/e sequences yielded similar reductions in Ca 2? sensitivity for PKA and PKCa and e, indicating that the effects of PKCa and e on Ca 2? sensitivity were independent of that of PKA ( Fig. 3c, d ; Table 2a ).
On average, K tr -max [tension redevelopment rate (s -1 ) at maximal Ca 2? concentration] was significantly increased after PKCa, PKCe and PKA incubation in failing cardiomyocytes (Table 2a) . However, it must be noted that the change in K tr -max in failing cells upon kinase treatments did not significantly differ from the increase observed in the (time) control incubations (Table 2a ). These results suggest that the kinases and phosphatase used have little, if any, effect on the kinetics of force redevelopment at saturating calcium concentration.
PKCa decreases Ca 2? sensitivity via cTnT phosphorylation
As observed in a previous study [14, 36] , analysis of baseline endogenous myofilament protein phosphorylation revealed significantly higher cMyBP-C and cTnI phosphorylation in donor samples in comparison to failing samples, while no significant differences in phosphorylation were observed for desmin, cTnT and MLC-2 (Fig. 4a) . F max and F pas did not significantly differ between failing (n = 56; F max 31.7 ± 1.5 kN/m 2 and F pas 1.6 ± 0.1 kN/ m 2 ) and donor (n = 20; F max 33.8 ± 3.0 kN/m 2 and F pas 1.8 ± 0.2 kN/m 2 ) cardiomyocytes, while Ca 2? sensitivity of the myofilaments was significantly higher in failing (5.66 ± 0.01; n = 54) compared to donor (5.50 ± 0.01; n = 20) myocardium. In addition the steepness of the pCaforce relationship (nH) was slightly lower in failing (3.48 ± 0.09; n = 54) compared to donor (3.85 ± 0.19; n = 20) cells (P \ 0.05). K tr -max was slightly, though not significantly, higher in failing (0.84 ± 0.02 s -1 ; n = 56) than in donor (0.77 ± 0.03 s -1 ; n = 20) cells. Previous analysis using two-dimensional gel electrophoresis revealed that endogenous cTnT phosphorylation is high (*63%), both in donor and failing myocardium [36] . To uncover functional effects of PKCa-mediated cTnT phosphorylation in human tissue, PKCa incubations were repeated after pretreatment of failing and donor cardiomyocytes with AP. AP significantly reduced cTnT phosphorylation to 15% of its original level in donor and to 17% in failing myocardium without dephosphorylation of cTnI (Fig. 5a, b) . AP treatment also significantly reduced phosphorylation of cMyBP-C (*30%) in donor myocardium, and of desmin (*30%) in failing tissue. Subsequent phosphorylation by PKCa of samples dephosphorylated by AP resulted in significant increases in cTnT phosphorylation in failing (170%) and in donor tissue (95%). In addition, PKCa significantly increased phosphorylation of cMyBP-C (*23%), desmin (*113%), cTnI (*160%) and MLC-2 (*80%) in failing tissue, while in AP pre-treated donor tissue, cTnT was the only protein phosphorylated by PKCa (Fig. 5c) .
After the massive dephosphorylation of cTnT, the effects of PKCa on cardiomyocyte function were studied. AP treatment resulted in an increase in Ca 2? sensitivity, which was similar in failing and donor tissue (Fig. 6a, b ; DpCa 50 = 0.09). Subsequent treatment with PKCa resulted in a decline in Ca 2? sensitivity to a level (pCa 50 after AP-PKCa: 5.60 ± 0.01 and 5.51 ± 0.02 in failing and donor, respectively) similar to that observed after PKCa treatment, without AP pretreatment (Table 2b ). The steepness of the force-pCa relation decreased upon AP in failing and donor cells and remained low after PKCa (Table 2b) . A similar decline in steepness of the Ca 2? sensitivity curve was observed in the time control experiments in the absence of kinase or phosphatase. AP treatment resulted in a small but significant increase in F max in failing cells (Fig. 6c) . In donor cells (Fig. 6d ) no effect on F max was observed. PKCa applied after AP treatment did not affect F max in both groups. AP also caused a significant increase in e Phosphorylation of myofilament proteins was expressed relative to the Sypro Ruby-stained cMyBP-C bands to correct for differences in protein loading. PKCa (n = 5) and PKCe (n = 2) both significantly increased phosphorylation of endogenous myosin binding protein C (cMyBP-C) and troponin I (cTnI), while effects on desmin and troponin T (cTnT) were only small. *P \ 0.05, PKC treatment versus control incubation in paired t test Basic Res Cardiol (2010) 105:289-300 293 failing and donor cells (Fig. 6e, f) , but subsequent PKCa treatment failed to restore the original levels.
Discussion
This study shows that PKC-mediated phosphorylation of cMyBP-C and cTnI as well as of cTnT cause a reduction of Ca 2? sensitivity of force development in human myocardium. No effects on maximal force generating capacity of the myofilaments were observed, neither upon direct PKC treatment nor following phosphatase pretreatment. On the basis of these data we propose that increased PKC activity in failing myocardium may depress systolic function of the heart as for the same intracellular Ca 2? concentration, the myofilament force generation and thereby developed pressure will be reduced. On the other hand, the reduced myofilament Ca 2? sensitivity may help myocardial relaxation as Ca 2? concentrations are increased in failing hearts [3, 9] .
PKCa and PKCe phosphorylation of cTnI and cMyBP-C decrease Ca 2? sensitivity in failing myocardium Direct incubation of the cardiomyocytes from failing hearts with saturating amounts of active PKCa and PKCe resulted in a decrease in Ca 2? sensitivity (Fig. 1 ). PKCa and PKCe incubations of failing tissue resulted in increased phosphorylation of cMyBP-C and cTnI. PKCa incubation resulted in higher phosphorylation of cTnI and PKCe in ; nH, steepness of the force-pCa curves * P \ 0.05, before versus after incubation in paired t test # Time control incubations higher phosphorylation levels of cMyBP-C, indicating isozyme specific substrate affinity. Although phosphorylation effects were diverse, the functional consequences of both PKC isoforms were quite similar.
It has previously been determined that cMyBP-C has PKC-phosphorylatable residues [24, 40] . However, so far no data has been published (to our knowledge) that directly link cMyBP-C phosphorylation with alterations in Ca 2? sensitivity. Our data suggest involvement of PKC-mediated cMyBP-C phosphorylation in the reduced Ca 2? sensitivity observed in failing tissue.
Kobayashi et al. [20] indicated that PKCe was able to phosphorylate PKA sites on mouse cTnI. Our previous study also showed that the active catalytic domain of PKC caused cross-phosphorylation of the PKA sites (Ser23/24) [35] . We addressed this issue for PKCa-and PKCe-mediated phosphorylation by performing experiments where incubations of PKCa or PKCe were followed by PKA as well as by incubations in the reverse order. The results showed that the shifts in Ca 2? sensitivity in failing myocardium did not depend on the sequence of application of PKA and PKCa/e. This indicates that the effects of the PKC isoforms and PKA were independent and that the PKCa/e-mediated effects were not caused by cross-phosphorylation of the PKA sites under our conditions. Kobayashi et al. [20] used the recombinant mouse cTnI and an excess of PKCe, therefore it is possible that the crossphosphorylation they observed does not occur under more physiological conditions or that it is more pronounced in mice than in human cTn.
PKCa decreases Ca 2? sensitivity via cTnT phosphorylation
Direct incubation of donor cells with PKCa did not alter Ca 2? sensitivity (Fig. 4b) , which is in line with minor effects of PKCa on protein phosphorylation of cMyBP-C, desmin, cTnI, cTnT and MLC2 (Fig. 4c) . The absence of functional effects of PKCa is most likely explained by the relatively high baseline phosphorylation status of cMyBP-C, cTnI and cTnT in donor myocardium. Because endogenous cMyBP-C and cTnI phosphorylation levels in donor tissue were high (Fig. 4a) and no major effects of PKCa on Ca 2? sensitivity and protein phosphorylation were observed (Fig. 4b, c) , the donor tissue was used as a tool to reveal functional effects of PKCa-mediated phosphorylation of cTnT.
AP treatment resulted in a massive decrease in cTnT phosphorylation in failing and donor myocardium. Subsequent treatment with PKCa solely increased phosphorylation of cTnT in donor myocardium, which made it possible to identify the role of cTnT upon phosphorylation by PKCa. Treatment with PKCa following AP treatment showed a significant reduction in Ca 2? sensitivity in both failing and donor tissue. These results indicate that AP is able to dephosphorylate sites on cTnT, which are subsequently targeted by PKCa and when phosphorylated reduce Ca 2? sensitivity. Overall, our results are in agreement with previous animal studies [17, 24, 40] indicating that functionally relevant targets of PKCa-and PKCe-mediated Ca [17, 34] are considered the main sites (phosphorylated sites based on human sequence). It has been proposed that the relative balance of phosphorylation of the three PKC sites on cTnI is important for the regulation of its function [32] . Pseudophosphorylation of Ser-42/Ser-44 significantly reduced the myofilament response to calcium and phosphorylation of Thr-143 induced an increase in sensitivity to calcium [7, 39] . Among the four phosphorylation sites on cTnT, Thr-203 appeared to be the most important for modulation of cTn function in that it inhibited force as well as its Ca 2? sensitivity [33] .
PKCa reduces passive force, but not maximal force
Rodent studies indicate that PKC-mediated phosphorylation results in a reduction of the maximum force generating capacity of the cardiomyocytes [8, 26, 32, 33] . A study using an in vitro motility assay suggested that this might also be the case in human tissue [2] . However, the present results did not show depression of force upon PKC treatment and indicate that caution should be exerted when extrapolating data obtained in rodent studies to force development in human cardiomyocytes. Cardiac cTnI and cTnT phosphorylation by PKC may occur at different sites in different species and may explain the absence of an effect of PKCa on F max in human cardiomyocytes. Only recently, using mass spectrometry Zabrouskov et al. [42] revealed a novel phosphorylation site (Ser-76 or Thr-77) in human cTnI, while no phosphorylation was observed at the sites mentioned above. A study in mice revealed that the PKCainduced reduction in F max critically depended on cTnT phosphorylation at Thr-203 [33] . Future studies should be performed to reveal which sites are phosphorylated by PKC in human myocardium. Recently Molnár et al. [25] showed that PKCa contributes to the maintenance of contractile force in human cardiomyocytes, which is in line with our Fig. 3 PKCa and e do not cross-phosphorylate the PKA sites (Ser23/24). After the first force-pCa series (control, before incubation) myocytes from failing hearts were incubated with PKCa or PKCe and a second force-pCa series was measured. Thereafter the myocytes were incubated with PKA, which saturates the PKA sites on cTnI and the third forcepCa series was measured (a, b). PKCa-PKA, n = 9; PKCe-PKA, n = 7. PKCa and PKCe caused a reduction in Ca and troponin I (cTnI) was significantly lower in failing (n = 10) compared to non-failing donor (n = 4) samples. *P \ 0.05, donor versus failing in unpaired t test. b PKCa treatment did not alter force characteristics of non-failing donor cardiomyocytes. c Average data using 10 lg/mL of PKCa in samples from donor (n = 4) hearts. In donor tissue the only significant effect was a small (9 ± 3%) increase in cMyBP-C phosphorylation. *P \ 0.05, kinase versus control incubation in paired t test least to some extent one of the contractile proteins determining F max . However, in human tissue the impact is rather small and the link with PKCa is not evident. PKCa treatment resulted in a small reduction of F pas both in donor and in failing cardiomyocytes, whereas PKCe had no significant effect but did show a similar trend (Table 2) . AP treatment caused a significant increase in F pas in both failing and donor cells but subsequent PKCa treatment did not restore the original levels. These results suggest that the effects of PKCa-mediated phosphorylation and AP-induced dephosphorylation on stiffness are independent, and indicate that at least two distinct phosphorylation sites, possibly on titin [4, 22, 41] , are involved in the modulation of passive stiffness of the cardiomyocytes. To address this issue, the effect of PKCa in titin phosphorylation after incubation with PKCa was investigated both in donor and failing tissue (Fig. 2) . However, no significant effect was observed. This could imply that phosphorylation of titin is not solely responsible for the decrease in passive force observed after PKCa. However, since titin may contain numerous phosphorylation sites with one or few PKCa dependent sites, it might be that our method is not sensitive enough to resolve the minor relative changes in titin phosphorylation as appeared to be the case for protein kinase G by Krüger et al. [21] .
As high F pas has been associated with high left ventricular end-diastolic pressure in patients with diastolic dysfunction [4] , the reduction in passive stiffness by PKCa-mediated phosphorylation might improve diastolic filling of the heart. Fig. 6 The effects of PKCa after dephosphorylation of cTnT by alkaline phosphatase (AP) in failing (n = 5) and donor (n = 4) tissue. Ca 2? sensitivity of force was increased after AP treatment and was subsequently reduced after PKCa treatment to the levels observed without AP pretreatment (a, b). AP treatment resulted in a minor but significant increase in maximum force (F max ) in failing tissue while in donor tissue no change was observed (c, d). Subsequent treatment with PKCa had no effect on F max . Passive force (F pas ) (e, f) was increased after AP in failing and donor tissue and remained elevated after PKCa treatment. *P \ 0.05, before versus after phosphatase/ kinase treatment in Bonferroni post hoc test
Limitations and conclusions
In this study the effects of the kinases and phosphatases on the phosphorylation levels are represented relative to basal phosphorylation levels for each protein. Although the changes in protein phosphorylation levels were relatively small, the functional changes were significant and may be physiologically relevant.
Since the transition to end-stage heart failure is accompanied by an increase in PKCa activity [6] it is surprising that the effects of PKCa are observed only in end-stage failing hearts and become visible in donor hearts only after dephosphorylation by alkaline phosphatase. It should be noted, however, that the endogenous phosphorylation levels in the explanted myocardium studied not necessarily reflect the in vivo situation. The lower levels of cMyBP-C and cTnI phosphorylation observed in end-stage failing compared to donor myocardium may reflect desensitisation of the b-adrenergic pathway. Moreover, it has been suggested that high catecholamine levels at the time of tissue procurement underlies the relative high levels of cMyBP-C and cTnI phosphorylation levels in donor myocardium [23] . Future studies in biopsy samples taken under well-controlled hemodynamic conditions with parallel measurements of blood catecholamines should be performed to address this issue. Nevertheless, the data presented in this study clearly indicate that changes in expression and activation of PKCa and PKCe in response to pathophysiological stressors or increased hemodynamic demands during exercise translate into alterations in contractile function in human myocardium.
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